Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2010
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumoursHervé Rubie, Birgit Geoerger, Didier Frappaz, et al.
Pediatric Blood & Cancer|July 25, 2020
New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioningVianney Poinsignon, Laura Faivre, Laurent Nguyen, et al.
Cancer Medicine|March 6, 2021
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumorsChristine Chevreau, Christophe Massard, Aude Flechon, et al.
Cancers|March 19, 2020
Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACCMabrouka Doghman-Bouguerra, Pascal Finetti, Nelly Durand, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2016
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid developmentFrançois Lemonnier, Rob A Cairns, Satoshi Inoue, et al.
Cancer Research|November 13, 2016
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted AgentsAntoine Azan, Peter J Caspers, Tom C Bakker Schut, et al.
Nature Communications|May 3, 2020
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancerClélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, et al.
Annals of Hematology|September 5, 2016
Familial hematological malignancies: new IDH2 mutationWalid-Sabri Hamadou, Violaine Bourdon, Sébastien Létard, et al.
Bulletin Du Cancer|March 1, 2018
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, et al.
Pageof 11